Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha,25-dihydroxyvitamin D3

J Nutr Sci Vitaminol (Tokyo). 1990 Feb;36(1):21-31. doi: 10.3177/jnsv.36.21.


We examined the immunoregulating effect of 22-oxa-1 alpha,25-dihydroxyvitamin D3 (22-oxa-1 alpha,25(OH)2D3), a synthetic analogue of vitamin D3 with an oxygen atom at C22 in the side chain skeleton, on spontaneously developing autoimmune disorders in MRL/Mp-lpr/lpr (MRL/l) mice. The oral administration of the compound significantly prolonged the average life span of the mice and showed a significant reduction in proteinuria. Histopathological investigations also revealed that pathological conditions such as renal arteritis, granuloma or arthritis of the knee joints were much lighter in the treated group than in the untreated group. Furthermore, the lymphocyte phenotypes in thymus, lymphnode, and spleen were partially normalized and became similar to those found in young control animals by the treatment with 22-oxa-1 alpha,25(OH)2D3. These results suggest that this compound inhibits the development of lupus nephritis in MRL/l mice and may be therapeutically effective on the mice.

MeSH terms

  • Animals
  • Antigens, Surface / immunology
  • Antineoplastic Agents* / pharmacology
  • Autoimmune Diseases / drug therapy
  • Autoimmune Diseases / pathology
  • Autoimmune Diseases / prevention & control*
  • Calcitriol / analogs & derivatives*
  • Calcitriol / pharmacology
  • Cholecalciferol / pharmacology*
  • Kidney / drug effects
  • Kidney / pathology
  • Knee Joint / drug effects
  • Knee Joint / pathology
  • Male
  • Mice
  • Mice, Inbred Strains
  • Organ Specificity
  • Proteinuria / pathology
  • Specific Pathogen-Free Organisms


  • Antigens, Surface
  • Antineoplastic Agents
  • Cholecalciferol
  • Calcitriol
  • maxacalcitol